Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Pfizer Seeks Japan Nod for BA.4/5-Tailored Vaccine for Ages 5-11
Pfizer and BioNTech on October 13 filed their COVID-19 vaccine adapted to the BA.4/5 strains of the Omicron variant for use in children aged five through 11 in Japan.The bivalent vaccine contains mRNA encoding the spike-protein of both original and…
To read the full story
Related Article
- Pfizer’s Bivalent COVID Vaccines Approved for Primary Series in Japan
August 3, 2023
- BA.4/5-Based Jab Filed for 6 Months to 4 Years in Japan: Pfizer/BioNTech
April 12, 2023
- Japan Starts Omicron Vaccine Rollout for Ages 5-11
March 8, 2023
- Japan Approves Pfizer’s Omicron-Tailored Vaccine for Ages 5-11
March 1, 2023
- Pfizer’s Omicron-Adapted Jab for Ages 5-11 in Line for Japan Approval
February 28, 2023
- Pfizer’s Omicron-Tailored Jab for Ages 5-11 on PAFSC Agenda for Feb. 27
February 16, 2023
BUSINESS
- Nipro to List Forxiga AG in June Ahead of Pricing Rule Shift
April 30, 2026
- Japan Drug Sales Top 11 Trillion Yen in FY2025, Keytruda Leads: Encise
April 30, 2026
- Taiho Moves Araris’ ADC into PI for Lymphoma in US
April 30, 2026
- FDA Accepts Zipalertinib NDA for EGFR Exon 20-Mutant Lung Cancer: Taiho
April 30, 2026
- Sandoz Poaches Regeneron’s Yohei Ishii as Japan Chief
April 30, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…